Challenging treatment for refractory acquired haemophilia A complicated with severe severe acute respiratory coronavirus 2 infection.
Blood Coagul Fibrinolysis
; 33(6): 342-347, 2022 Sep 01.
Article
in English
| MEDLINE | ID: covidwho-2001485
ABSTRACT
Immunosuppressive treatment and bypassing agents are used to treat acquired haemophilia A (AHA). On the other hand, COVID-19 infection induces a hypercoagulable state. Managing bleeding, risk of thrombosis, bypassing agents, active infection and immunosuppressive treatment can be challenging. A 72-year-old man was diagnosed with acquired hemophilia A. He received steroids, rituximab and recombinant activated factor VII (rFVIIa). He developed severe SARS-CoV-2 infection. Due to thrombotic risk, he received low-molecular-weight heparin (LMWH) and developed an iliopsoas hematoma. Because of the risk of thrombosis, treatment with recombinant porcine FVIII (rpFVIII) was requested. Tocilizumab was administered for treatment of SARS-CoV-2 infection and unexpected improvement of FVIII levels was noted. Concluding, rpFVIII treatment was well tolerated and effective, easy to monitor and to administer. Tocilizumab may play a role as immunosuppressive treatment for AHA. The role of LMWH remains to be established in patients with coagulopathies.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Pneumonia
/
COVID-19
/
COVID-19 Drug Treatment
/
Hemophilia A
Type of study:
Case report
/
Prognostic study
Topics:
Long Covid
Limits:
Animals
/
Humans
/
Male
Language:
English
Journal:
Blood Coagul Fibrinolysis
Journal subject:
Vascular Diseases
/
Hematology
Year:
2022
Document Type:
Article
Affiliation country:
MBC.0000000000001149
Similar
MEDLINE
...
LILACS
LIS